Discussion on the Cost–Effectiveness Analysis of the CALGB/Alliance Trial and the Use of Zoledronic Acid Generic in Women With Metastatic Breast Cancer
Journal of Clinical Oncology (JCO) Podcast · Dominique Levêque
October 12, 20178m 13s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The paper examines the cost-effectiveness of schedules of bone-modifying agents in patients with breast cancer and skeletal metastases and supports the 3-month administration of the generic zoledronic acid in terms of cost and efficacy.